Literature DB >> 2983137

Preventive and enhancing effects of retinoids on the development of naturally occurring tumors of skin, prostate gland, and endocrine pancreas in aged male ACI/segHapBR rats.

M Ohshima, J M Ward, M L Wenk.   

Abstract

The effects of dietary retinoids on the development of naturally occurring tumors in retired breeder male ACI/segHapBR rats were investigated. Groups of rats (21-25 mo of age, an age when early neoplasms first appear and tumor incidences are generally low) were fed diets containing 1 of 3 retinoids--all-trans-N-4-(4-hydroxyphenyl)retinamide (4-HPR), 783 mg/kg diet; all-trans-N-(4-pivaloyloxyphenyl)retinamide (4-PPR), 951 mg/kg; or all-trans-4-N-(2-hydroxyethyl)retinamide (2-HER), 687 mg/kg--or control diet for up to 54 weeks (average, 33 wk). Rats were maintained until less than 20% remained and the experiment was terminated. Contributing causes of death were determined, and a complete necropsy was performed for each rat. There was no difference between the retinoid-treated rats and control rats in the average age at death (30-31 mo) or in the average experimental survival time (29-35 wk), in the proportions of tumor-bearing rats (95.6-100%), or in the average number of organs with tumor per rat (2.1-2.5). The incidences of pancreatic islet cell adenoma and skin tumors were significantly different between control and some retinoid-treated groups. 4-PPR and 2-HER significantly enhanced pancreatic islet cell adenoma yields (P less than .025 and 0.05, respectively) whereas 4-HPR significantly inhibited epithelial and connective tissue skin tumor yields (P less than .025). Incidences of skin and prostate tumors were lower than in controls, but not significantly, in rats receiving 4-PPR and 2-HER. Most of the islet cell adenomas were shown, by avidin-biotin-peroxidase complex immunocytochemistry, to be insulinomas. 4-HPR would seem to be the most effective retinoid in the group, inasmuch as it prevented skin tumor development, may have slightly decreased the incidence of prostate tumors, and did not enhance islet cell tumor incidence.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2983137

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  6 in total

Review 1.  Retinoid pathway and cancer therapeutics.

Authors:  Nathan Bushue; Yu-Jui Yvonne Wan
Journal:  Adv Drug Deliv Rev       Date:  2010-08-03       Impact factor: 15.470

2.  Fenretinide targets chronic myeloid leukemia stem/progenitor cells by regulation of redox signaling.

Authors:  Yanzhi Du; Yuan Xia; Xiaoling Pan; Zi Chen; Aihua Wang; Kankan Wang; Junmin Li; Ji Zhang
Journal:  Antioxid Redox Signal       Date:  2013-10-24       Impact factor: 8.401

3.  Fenretinide targeting of human colon cancer sphere cells through cell cycle regulation and stress-responsive activities.

Authors:  Lanlan Liu; Jiansheng Liu; Haiwei Wang; Hui Zhao; Yanzhi Du
Journal:  Oncol Lett       Date:  2018-08-13       Impact factor: 2.967

4.  Induction and intracellular localization of Nur77 dictate fenretinide-induced apoptosis of human liver cancer cells.

Authors:  Hui Yang; Nathan Bushue; Pengli Bu; Yu-Jui Yvonne Wan
Journal:  Biochem Pharmacol       Date:  2009-11-11       Impact factor: 5.858

5.  Flow Cytometric Analysis of 4-HPR-induced Apoptosis and Cell Cycle Arrest in Acute Myelocytic Leukemia Cell Line (NB-4).

Authors:  Shahrzad Soleymani Fard; Mahmood Jeddi-Tehrani; Mohammad Mehdi Akhondi; Mehrdad Hashemi; Ali M Ardekani
Journal:  Avicenna J Med Biotechnol       Date:  2010-01

6.  Pathology of aging female SENCAR mice used as controls in skin two-stage carcinogenesis studies.

Authors:  J M Ward; R Quander; D Devor; M L Wenk; E F Spangler
Journal:  Environ Health Perspect       Date:  1986-09       Impact factor: 9.031

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.